LLY ▼ -0.1% - Eli Lilly and Company $LLY - Lilly's oral GLP-1, Foundayo (orforglipron), was associated with significant reductions in predicted long-term risk of type 2 diabetes and cardiovascular disease 01-OCT-2026 07:01 AM ET